

Johnston-Willis Hospital

Business Office
1401 Johnston-Willis Drive
P.O. Box C-35003
Richmond, Va. 23235-0003
(804) 320-2900

March 27, 1985

85 APR 1 AIO: 17

Paul R. Guinn
U. S. Nuclear Regulatory Commission
Region II, Nuclear Materials Safety Section
101 Marietta Street, N.W.
Suite 2900
Atlanta, Georgia 30303

Dear Mr. Guinn:

Johnston-Willis Hospital operates its nuclear medicine and radiation therapy programs under NRC license #45-02888-01. A change in our NRC license to include our new radiation therapy facility and our radiation therapist, Doctor Richard Belgrad, was accomplished with Amendment Number 39 (copy attached). However, while this amendment increased the types of materials we were authorized to possess under condition 6, it did not alter the authorized users, under condition 12, in a consistent manner. Thus, certain license was granted beyond our intent. We request that this situation be corrected.

At the same time, we request that the authorized users per condition 12 additionally include Khadijeh S. Zarkoob, M.D. with authorization for Group IV and Group VI materials. Doctor Zarkoob is certified by the American Board of Radiology having received her certification in Radiation Therapy and Oncology in June of 1983. NRC Form 313M Supplements A and B are attached for your review. Doctor Zarkoob was trained in radiation therapy at the Medical College of Virginia under NRC licenses #45-00048-17 and #45-00048-19.

With the above changes, we believe Condition 12 should read as:

(NAME)

(USES)

Russell O. Briere, M.D.

All authorized uses (as per condition 9) of Group I, II, III, IV, V materials; by-product materials listed in Section 31.11(a) of 10 CFR 31; and Xenon 133

8509250394 850826
REG2 LIC30
45-02888-01 PDR

Official Copy

HCA Hospital Corporation
of America

John L. Thornton, M.D.

Groups I, II and III
In vitro studies
Xenon 133
Phosphorus 32 soluble phosphate for treatment of polycythemia vera, leukemia and bone metastases

Hampton R. Bates, Jr., M.D.

Groups I, II and III
In vitro studies
Xenon 133
Iodine 131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma

Fabio Gutierrez, M.D.

Groups I, II and III
In vitro studies
Xenon 133

Vernon M. Sylvest, M.D.

Groups I and II
In vitro studies
Xenon 133

George W. Thomas, M.D.

Groups I and II
In vitro studies
Xenon 133

Richard Belgrad, M.D.


Groups IV and VI

Khadijeh S. Zarkoob, M.D.

Groups IV and VI

Your attention to this matter is very much appreciated.

Sincerely,



Patrick Romano
Assistant Administrator

Enclosures: Amendment Number 39
NRC Form 313M, A and B

PR:ams

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1 NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER Khadijeh S. Zarkoob	2 STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE Virginia - Indiana
--	---

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C
Board of Radiology	Radiation Therapy & Oncology	June, 1983

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		LECTURE/ LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours) D
a. RADIATION PHYSICS AND INSTRUMENTATION	Medical College of Virginia Jan., 1980 - June, 1983	150	
b. RADIATION PROTECTION	Medical College of Virginia Jan, 1980 - June, 1983	20	
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	Medical College of Virginia Jan, 1980 - June, 1983	100	
d. RADIATION BIOLOGY	Medical College of Virginia Jan, 1980 - June, 1983	150	
e. RADIOPHARMACEUTICAL CHEMISTRY			

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
P - 32		Medical College of Virginia	5 years	IP Infusion
Cs - 137		Medical College of Virginia	5 years	Intracavitary
I - 125		Medical College of Virginia	5 years	Interstitial Implant
Ir - 192		Medical College of Virginia	5 years	Interstitial Implant
Sr - 90		Medical College of Virginia	5 years	Surface Applica- tor

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. APPLICANT PHYSICIAN'S NAME AND ADDRESS			KEY TO COLUMN C PERSONAL PARTICIPATION SHOULD CONSIST OF: 1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage. 2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data. 3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.
FULL NAME Richard Belgrad, M.D.			
STREET ADDRESS Johnston Willis Hospital 1401 Johnston Willis Drive			
CITY Richmond	STATE VA	ZIP CODE 23235	

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION		
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES		
	IN VITRO STUDIES		
OTHER			
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING		
P-32	EYE TUMOR LOCALIZATION		
Se-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY		
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
OTHER			
Tc-99m	BRAIN IMAGING		
	CARDIAC IMAGING		
	THYROID IMAGING		
	SALIVARY GLAND IMAGING		
	BLOOD POOL IMAGING		
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING		
	LUNG IMAGING		
	BONE IMAGING		
OTHER			

RECEPTOR STATEMENT (Continue)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloidal)	INTRACAVITARY TREATMENT	5	
I-131	TREATMENT OF THYROID CARCINOMA		
	TREATMENT OF HYPERTHYROIDISM		
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT	250	
I-125 or Ir-192	INTERSTITIAL TREATMENT	40	
Co-60 or Cs-137	TELE THERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE	40	
	RADIO PHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sn-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS		
Other			

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

January, 1980 - June, 1983

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR
Tapan Hazra, M.D.

b. NAME OF INSTITUTION
Medical College of Virginia

c. MAILING ADDRESS
Box 58

d. CITY
Richmond, VA 23298

5. MATERIALS LICENSE NUMBER(S)

6. PRECEPTOR'S SIGNATURE

Richard Belgrad / K2

7. PRECEPTOR'S NAME (Please type or print)

Richard Belgrad, M.D.

8. DATE

3-7-85